Information Provided By:
Fly News Breaks for November 22, 2016
AXGN
Nov 22, 2016 | 08:48 EDT
Lake Street analyst Bruce Jackson upgraded AxoGen to Buy saying the "story is revived' following yesterday's analyst meeting. The company unveiled a new product for adhesion prevention called Avive along with two other pipeline development programs in breast reconstruction and lower limb iatrogenic nerve injury, Jackson tells investors in a research note. The analyst raised his price target for the shares to $11 from $9.
News For AXGN From the Last 2 Days
There are no results for your query AXGN